Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02465957 · ClinicalTrials.gov registry record · Phase 2
QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)
A Phase 2 study, sponsored by ImmunityBio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT02465957 is a Phase 2 study that was terminated before completion, run by ImmunityBio. The registered enrollment target is 7 participants.
The verdict
NCT02465957, a Phase 2 study, was terminated before completion, sponsored by ImmunityBio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
Phase II study to determine the effects of aNK infusions in combination with ALT-803 in patients with stage III (IIIB) or stage (IV) merkel cell carcinoma (MCC).
Interventions
- BIOLOGICAL aNK (NK-92)
- BIOLOGICAL aNK (NK-92) + N-803
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-09-24 |
| Est. Completion | 2018-03-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02465957
The ClinicalTrials.gov registry entry for NCT02465957 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which aNK (NK-92) is the first listed.
NCT02465957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02465957 about?
NCT02465957 is a clinical study titled "QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)". Phase II study to determine the effects of aNK infusions in combination with ALT-803 in patients with stage III (IIIB) or stage (IV) merkel cell carcinoma (MCC).
What is the current status of trial NCT02465957?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2015-09-24. Estimated completion is 2018-03-19.
What interventions are being tested in trial NCT02465957?
The interventions under investigation include: aNK (NK-92) (BIOLOGICAL), aNK (NK-92) + N-803 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02465957?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.